Golden
Cara Therapeutics

Cara Therapeutics

A company developing treatments for pain, inflammation and pruritus

All edits by  Dawson Sewell 

Edits on 29 Mar 2019
Dawson Sewell
Dawson Sewell edited on 29 Mar 2019 4:19 pm
Edits made to:
Infobox (+3 properties)
Article (+904/-795 characters)
Categories (+1/-2 topics)
Related Topics (+1 topics)

Article

Cara Therapeutics is a publicly held biotechnologybiotechnology company based in Stamford, Connecticut that was founded in 2004 by Derek Chalmers, Frederique Menzaghi, and Michael E. Lewis. It is focused on developing therapeutics to treat pain, inflammation, and pruritus. This is done by selectively targeting peripheral kappa opiod receptors (KORs). 



Cara is developing a proprietrary class of product candidates that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain and pruritus (itch) without inducing many of the side effects typically associated with other pain and itch therapeutics.

...

Cara is developing a proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain and pruritus (itch) without inducing many of the side effects typically associated with other pain and itch therapeutics.

Products

CR845

...



Korsuva

The product, Korsuva, has been formulated both as an IV and oral formulation and is being studied for acute pain, chronic pain, and uremic pruritus (itch). An injectible version of Korsuva is ready for commercialization, while the oral version for Puritus CKD and Pruritus CLD are in Phase 3 and Phase 2 of clinical studies respectively. An IV Difelikefalin version of CR845 is ready for commercialization for use in post-op settings and another oral difelikefalinDifelikefalin version has completed Phase 3 clinical studies for chronic pain and is progressing to commercialization.

CR701

Cara also has a product in preclinical development. CR701 selectively modulates CB receptors without targeting CNS cannabinoid receptors. It is intended to be developed as a therapeutic approach for neuropathic pain. The product has been evaluated in rodent models of neuropathic pain that produces both hyperalgesia (sensitization of nerve endings to painful stimuli) and allodynia (painful perception of innocuous stimuli) comparable to human conditions.

...

Cara also has a product in preclinical development. CR701 selectively modulates CB receptors without targeting CNS cannabiniod receptors. It is intended to be developed as a therapeutic approach for neuropathic pain. The product has been evaludated in rodent models of neuropathic pain that produces both hyperalgesia (sensitization of nerve endings to painful stimuli) and allodynia (painful perception of innocuous stimuli) comparable to human conditions.

Infobox

Date incorporated
July 2, 2004

Categories

Related Topics

Edits on 15 Jan 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 15 Jan 2019 2:13 pm
Edits made to:
Article (+12/-12 characters)

Article

The product, Korsuva, has been formulated both as an IV and oral formulation and is being studied for acute pain, chronic painchronic pain, and uremic pruritus (itch). An injectible version of Korsuva is ready for commercialization, while the oral version for Puritus CKD and Pruritus CLD are in Phase 3 and Phase 2 of clinical studies respectively. An IV Difelikefalin version of CR845 is ready for commercialization for use in post-op settings and another oral difelikefalin version has completed Phase 3 clinical studies for chronic pain and is progressing to commercialization.

No more activity to show.